Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Patently Dumb: America’s current patent system inhibits innovation. Here’s how to fix it
Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries
AbbVie’s New Hepatitis C Treatment Won’t Cure Patient Access Issue
WHO moves to widen access to generic Sovaldi in dozens of countries
After India, I-MAK files legal challenge against Gilead’s hepatitis C drug sofosbuvir in China
Building on 2015 rejection of Gilead’s patent application for hepatitis C, legal challenge to Gilead’s remaining patent in China that blocks hep C treatment for up to 13 million people
Gilead faces fresh patent challenges over hepatitis C drugs in India
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Sovaldi patent ruling not a game-changer, yet NGO, drugmaker both weigh appeals to partial ruling.
Partial Revocation Of EPO Patent On Sofosbuvir, Key For Hepatitis C